OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders

Stock Information for Orchestra BioMed Holdings Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Orchestra BioMed Holdings Inc Com

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
Entera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEO
Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates
Entera Bio to Participate in Upcoming Events
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.